高变异药物硫酸氢氯吡格雷片的人体生物等效性及饮食影响

李文博,丁黎*,任昱全,丁雯,吴琰,潘虹

中国药学杂志 ›› 2014, Vol. 49 ›› Issue (16) : 1437-1441.

PDF(936 KB)
PDF(936 KB)
中国药学杂志 ›› 2014, Vol. 49 ›› Issue (16) : 1437-1441. DOI: 10.11669/cpj.2014.16.016
论著

高变异药物硫酸氢氯吡格雷片的人体生物等效性及饮食影响

  • 李文博1,丁黎1*,任昱全2,丁雯1,吴琰1,潘虹1
作者信息 +

Bioequivalence of Highly Variable Drug Clopidogrel Bisulfate and Food Effects on Its Pharmacokinetics

  • LI Wen-bo1, DING Li1*, REN Yu-quan2, DING Wen1, WU Yan1, PAN Hong1
Author information +
文章历史 +

摘要

目的 评价空腹和餐后服用两种硫酸氢氯吡格雷片的生物等效性,考察饮食对氯吡格雷在中国人体内的药动学影响。方法 针对氯吡格雷的高变异性,根据文献报道的该药的个体内变异系数等数据计算空腹给药试验所需受试者例数为70例;根据空腹试验的结果计算餐后给药生物等效性试验所需受试者例数为56例。两次试验分别采用健康男性受试者进行双周期双交叉(清洗期为7 d)单次口服受试制剂和参比制剂300 mg的试验方法。结果 空腹口服受试制剂与参比制剂后,氯吡格雷的ρmax分别为(5.78±4.93)、(6.17± 6.76)ng·mL-1tmax分别为(0.71±0.33)、(0.76±0.40)h,AUC0-30 h分别为(8.83±6.72)、(9.35±7.93)ng·h·mL-1,相对生物利用度为(107.3±50.5)%;餐后口服受试制剂与参比制剂后,氯吡格雷的ρmax分别为(30.9±12.5)、(30.1±13.3)ng·mL-1tmax分别为(1.9±0.6)、(1.9±0.6)h,AUC0-30h分别为(65.0±21.6)、(65.8±22.3)ng·h·mL-1,相对生物利用度为(102.0±23.1)%。两种硫酸氢氯吡格雷片之间在空腹和高脂餐给药后药动学参数均无显著差异(P>0.05)。结论 对高变异药物氯吡格雷的生物等效性样本量设计合理。受试制剂和参比制剂在空腹给药和高脂餐后给药情况下均具有生物等效性。与空腹给药相比,高脂餐后给药,tmax延后1.2 h,ρmax和AUC0-30 h分别增大5倍和7倍左右。

Abstract

OBJECTIVE To investigate the bioequivalence of clopidogrel bisulfate under fasting and fed conditions and the effect of food on the pharmacokinetics of clopidogrel in chinese volunteers.METHODS Based on the high variability of clopidogrel and its intra-subject variation coefficient data reported in the literatures, the sample size of the bioequivalence evaluation of clopidogrel tablets under fasting condition was estimated and designed to 70 subjects. Based on the fasting test results, the sample size of the bioequivalence evaluation of clopidogrel tablets in fed condition was designed to 56 subjects. Both of the studies were designed to the open, randomized and crossover tests in which a single oral dose of 300 mg clopidogrel bisulfate tablets was administered to healthy male volunteers.RESULTS The pharmacokinetic parameters of clopidogrel in fasting condition for the test and reference tablets were as follows:ρmax(5.78±4.93)vs.(6.17±6.76)ng·mL-1,tmax(0.71±0.33)vs.(0.76±0.40)h,AUC0-30 h(8.83±6.72)vs.(9.35±7.93)ng·h·mL-1, and the relative bioavailability of clopidogrel was(107.3±50.5)%;the pharmacokinetic parameters for the test and reference tablets in fed state were as follows:ρmax(30.9±12.5)vs.(30.1±13.3)ng·mL-1,tmax(1.9±0.6)vs.(1.9±0.6)h,AUC0-30 h (65.0±21.6)vs.(65.8±22.3)ng·h·mL-1,and the relative bioavailability was(102.0±23.1)%. There were no significant differences in pharmacokinetic parameters between two tablets (P> 0.05).CONCLUSION The sample size is reasonably designed for the bioequivalence of highly variable drug clopidogrel tablets. The test and reference tablets are considered bioequivalent in human. The ρmaxand AUC0-30 h increase 5-fold and 7-fold,and tmax increase 1.2 h in fed condition compared to the fasting condition.

关键词

高变异 / 样本量 / 氯吡格雷 / 生物等效性 / 饮食影响 / 液相二级质谱联用

Key words

highly variable / sample size / clopidogrel / bioequivalence / food effect / LC-MS/MS

引用本文

导出引用
李文博,丁黎*,任昱全,丁雯,吴琰,潘虹. 高变异药物硫酸氢氯吡格雷片的人体生物等效性及饮食影响[J]. 中国药学杂志, 2014, 49(16): 1437-1441 https://doi.org/10.11669/cpj.2014.16.016
LI Wen-bo, DING Li*, REN Yu-quan, DING Wen, WU Yan, PAN Hong. Bioequivalence of Highly Variable Drug Clopidogrel Bisulfate and Food Effects on Its Pharmacokinetics[J]. Chinese Pharmaceutical Journal, 2014, 49(16): 1437-1441 https://doi.org/10.11669/cpj.2014.16.016
中图分类号: R969   

参考文献

[1] ZHAGN Q S,ZOU J,ZHAO D,et al.Research progress of a new antiplatelet agent-clopidogrel.Chem Ind Eng Prog(化工进展),2003,22(7):689-693.[2] HU J R,JIANG H,LIU X S. Research progress of antiplatelettherapy-aspirin combined with clopidogrel.J Chin Pharm(中国药房),2013,24(8):750-753.[3] ZHANG C L. Review of the relationship between polymorphisms of cytochrome P450 2C19 and clopidogrel responsiveness . Adv Cardiovasc Dis(心血管病进展),2011,32(6):858-862.[4] FRELINGER III A, BHATT D, LEE R,et al.Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1),noncompliance,diet, smoking, co-medications(Including Proton Pump Inhibitors),and pre-existent variability in platelet function.J Am Coll Cardiol, 2013,61(2): 872-879.[5] HUANG Q,WEI C M.Research of the bioequivalence of highly variable drugs .Chin J Clin Pharmacol(中国临床药理学杂志),2007,12(8):841-844.[6] SFDA. Notes for guidance on the investigation of bioavailability and bioequivalence(化学药物制剂人体生物利用度和生物等效性研究技术指导原则) . 2005.[7] JIANG J J,YAN Y,HUANG Y L,et al. Pharmacokinetics and boequivalence study of domestic made clopidogrelin healthy Chinese volunteers .Chin Circu J(中国循环杂志),2012,27(1):45-48.[8] CHEN M C,LU C T,JIA Y Y,et al.Determination of clopidogrel in human plasma by LC-MS/MS and its application to bioequiavailability .Chin J Hosp Pharm(中国医院药学杂志),2012,32(6):421-424.[9] GAO L Y,LIU C X. Sample size of the bioequivalence study . Chin J Clin Pharmacol Ther(中国临床药理学与治疗学杂志),1997,2(2):127-128. FILIPE A,ALMEIDA1 S,SPNOLA F,et al.Single-dose randomized, open-label, 2-waycrossover bioequivalence study of clopidogrel75 mg tablet in healthy volunteers underfasting conditions.Int J Clin Pharm Rapeutics,2009, 47(3):187-194. EMEA.CHMP Assessment report for clopidogrelmylan . 2009-10-14 .http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001134/WC500029508.pdf. EMEA .Assessment report for clopidogreltevapharma . 2009-08-12 (2010-06-14) .http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001053/WC500031168.pdf . EMEA.Assessment report for clopidogrelmylanpharma. 2009-11-09 . http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001189/WC500029704.pdf . NIROGIR,KANDIKEREV,MUDIGONDAK.Effect of food on bioavailability of a single oral dose of clopidogrelin healthy male subjects .Arzneimittel-forschung-drug Research,2006, 56(11):735-739. HURBIN F,BOULENC X,DASKALAKIS N,et al.Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state:A randomized crossover study of healthy men.J Clin Pharmacol, 2012, 52(10): 1506-1515. WANG L,ZHANG Y H.Pay attention to effect of food on the bioavailability .Chin Pharm News(中国医药报),2011-7-1(6).
PDF(936 KB)

Accesses

Citation

Detail

段落导航
相关文章

/